Reata Pharmaceuticals Inc (NASDAQ:RETA) has been given a consensus recommendation of “Hold” by the eleven ratings firms that are presently covering the firm, MarketBeat reports. Three investment analysts have rated the stock with a sell rating and eight have issued a buy rating on the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $54.71.
A number of analysts have issued reports on the stock. Zacks Investment Research downgraded shares of Reata Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday. BidaskClub downgraded shares of Reata Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, January 31st. Cowen reiterated a “buy” rating on shares of Reata Pharmaceuticals in a report on Thursday, December 14th. ValuEngine downgraded shares of Reata Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, November 9th. Finally, Robert W. Baird reiterated a “buy” rating and issued a $47.00 price target on shares of Reata Pharmaceuticals in a report on Tuesday, October 24th.
In other Reata Pharmaceuticals news, major shareholder James W. Traweek, Jr. bought 17,000 shares of Reata Pharmaceuticals stock in a transaction dated Friday, December 29th. The shares were purchased at an average cost of $28.47 per share, for a total transaction of $483,990.00. Following the acquisition, the insider now directly owns 35 shares in the company, valued at approximately $996.45. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Cpmg Inc bought 200,000 shares of Reata Pharmaceuticals stock in a transaction dated Thursday, December 14th. The stock was acquired at an average price of $24.79 per share, for a total transaction of $4,958,000.00. Following the completion of the acquisition, the director now owns 113 shares in the company, valued at $2,801.27. The disclosure for this purchase can be found here. Over the last 90 days, insiders bought 409,925 shares of company stock worth $10,359,964. Insiders own 44.00% of the company’s stock.
Shares of Reata Pharmaceuticals (NASDAQ RETA) traded down $0.36 during midday trading on Friday, reaching $26.73. 192,300 shares of the company’s stock were exchanged, compared to its average volume of 171,848. The company has a debt-to-equity ratio of -0.15, a quick ratio of 3.18 and a current ratio of 3.18. The company has a market cap of $698.00, a P/E ratio of -16.83 and a beta of -2.52. Reata Pharmaceuticals has a one year low of $19.48 and a one year high of $40.88.
TRADEMARK VIOLATION WARNING: This news story was first posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this news story on another site, it was copied illegally and reposted in violation of international copyright & trademark law. The correct version of this news story can be read at https://www.chaffeybreeze.com/2018/02/20/brokerages-set-reata-pharmaceuticals-inc-reta-target-price-at-54-71.html.
About Reata Pharmaceuticals
Reata Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or life-threatening diseases.
Receive News & Ratings for Reata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.